Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Decadelong study finds smoking worsens sickle cell retinopathy (opens in a new tab)

medicalxpress.com · 2026-09-30

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study. One other point was not covered by the paper.

  • 2 supported
  • 2 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two of five claims overstate the study. Two of five check out. One claim the study doesn't address.

  • 2 supported
  • 2 overstated
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedA 10-year retrospective study of adults with sickle cell retinopathy treated at Wilmer Eye Institute found that active smoking is a strong modifiable risk factor for disease progression.View evidenceHide evidence

As statednearly three times as likely to experience progression; hazard ratio 2.78

Why this verdict

The abstract profile supports an observational association between active smoking at PSR diagnosis and progression from baseline PSR to more advanced PSR, with HR 2.78 (95% CI 1.50–5.16). The story’s phrasing broadens this to smoking as a strong modifiable risk factor for sickle cell retinopathy progression generally; the supplied evidence is narrower and observational, so causal/actionability implications should be treated cautiously.

1

Study evidence

Active smoking at PSR diagnosis was associated with increased hazard of progression to more advanced PSR.HR 2.78 (95% CI 1.50–5.16)

“Cox-proportional hazards models were used to evaluate factors associated with progression.”
Claim 2 of 5OverstatedThe article says the findings support smoking cessation and routine retina exams as actionable measures to help prevent vision loss and reinforce existing screening recommendations for people with sickle cell disease.View evidenceHide evidence

Why this verdict

The paper profile says the observed association supports smoking cessation and closer monitoring with timely intervention among active smokers with PSR, and supports longitudinal ophthalmic surveillance. The story’s broader framing that smoking cessation and routine retina exams are actionable measures to help prevent vision loss for people with sickle cell disease goes beyond the abstract evidence: the study did not test cessation or screening interventions, did not directly measure prevention of vision loss as stated, and the smoking association is specific to active smoking at PSR diagnosis and progression to more advanced PSR.

1

Study evidence

Progression from baseline nonproliferative sickle retinopathy (NPSR) to proliferative sickle retinopathy (PSR) occurred in 10.7% of eyes.10.7%

“DESIGN: Retrospective Cohort Study.”
2

Study evidence

Active smoking at PSR diagnosis was associated with increased hazard of progression to more advanced PSR.HR 2.78 (95% CI 1.50–5.16)

“Cox-proportional hazards models were used to evaluate factors associated with progression.”
Claim 3 of 5Not coveredThe study followed 317 adults with sickle cell disease (620 eyes total) over up to 11 years using electronic medical records and modern imaging/tests, and is described as the largest longitudinal U.S. study of adults with sickle cell retinopathy using modern methods.View evidenceHide evidence

As stated317 adults; 620 eyes; 10-year retrospective study

Why this verdict

The abstract profile supports a retrospective Wilmer cohort from 2013–2023 with 317 patients/620 eyes, EMR extraction, Goldberg staging by fluorescein angiography or ultra-widefield fundus photography, and qualitative OCT assessment. However, the claim that it is the largest longitudinal U.S. study of adults with sickle cell retinopathy using modern methods is not verifiable from the supplied abstract-level profile.

1

Study evidence

Progression from baseline nonproliferative sickle retinopathy (NPSR) to proliferative sickle retinopathy (PSR) occurred in 10.7% of eyes.10.7%

“DESIGN: Retrospective Cohort Study.”
2

Study evidence

Qualitative macular OCT findings did not correlate with baseline peripheral vascular stage and were not associated with SCR progression.

“Qualitative assessment of macular optical coherence tomography findings did not correlate with baseline peripheral vascular stage and were not associated with SCR progression.”
Claim 4 of 5SupportedAmong eyes that started with nonproliferative sickle cell retinopathy, 10.7% progressed to proliferative disease; among eyes already proliferative at baseline, 17% showed additional progression over follow-up.View evidenceHide evidence

As stated36 eyes (10.7%); 44 eyes (17%)

Why this verdict

The abstract profile directly reports progression in 10.7% of baseline NPSR eyes and 17.0% of at-risk baseline PSR eyes, with median follow-up of 7.8 and 11.1 years respectively. The exact numerator counts in the story’s magnitude field are not separately exposed in the supplied profile, but the main percentage claim is supported.

1

Study evidence

Progression from baseline nonproliferative sickle retinopathy (NPSR) to proliferative sickle retinopathy (PSR) occurred in 10.7% of eyes.10.7%

“DESIGN: Retrospective Cohort Study.”
2

Study evidence

Active smoking at PSR diagnosis was associated with increased hazard of progression to more advanced PSR.HR 2.78 (95% CI 1.50–5.16)

“Cox-proportional hazards models were used to evaluate factors associated with progression.”
Claim 5 of 5SupportedThe researchers did not find statistically significant associations between progression and several other factors, including age at diagnosis, sex, genotype, hydroxyurea use, transfusions, chronic red cell exchanges, bone marrow transplantation, or lifetime smoking history.View evidenceHide evidence

Why this verdict

The abstract profile states that age at diagnosis, sex, genotype, hydroxyurea use, blood transfusions, chronic red cell exchanges, bone marrow transplantation, and lifetime smoking history were not associated with sickle cell retinopathy progression in the reported Cox models.

1

Study evidence

Active smoking at PSR diagnosis was associated with increased hazard of progression to more advanced PSR.HR 2.78 (95% CI 1.50–5.16)

“Cox-proportional hazards models were used to evaluate factors associated with progression.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Active smoking finding is specifically an association between active smoking at PSR diagnosis and progression to more advanced PSR, not a demonstrated causal effect or a general predictor of all SCR progression stages.

    The story notes current smoking and says causation is not proven, but its main framing broadens the result to disease progression generally and does not preserve the PSR-at-diagnosis to more-advanced-PSR specificity.

    From Retrospective cohort; time-to-event analysis with Cox proportional hazards regression

  • Qualitative macular OCT findings did not correlate with baseline peripheral vascular stage and were not associated with SCR progression.

    This secondary imaging result is part of the paper profile but is not reflected in the supplied story presentation.

    From Retrospective cohort imaging sub-study

  • Retrospective EMR-based design creates potential for missing/incomplete data and unmeasured confounding.

    The story identifies the study as retrospective and says it does not prove causation, but it does not explicitly acknowledge missing EMR data or unmeasured confounding as limitations.

    From Retrospective cohort (secondary data from EMR); Retrospective cohort; time-to-event analysis with Cox proportional hazar

  • Eye-level analysis used 620 eyes from 317 patients, and the abstract profile notes that inter-eye correlation handling is not described.

    The story reports eyes and patients but does not mention the methodological limitation related to non-independence of two eyes from the same person.

    From Retrospective cohort (secondary data from EMR)

6 things the story did carry across
  • Retrospective longitudinal Wilmer Eye Institute cohort, 2013–2023, using EMR data from 317 patients/620 eyes with sickle cell retinopathy.
  • Progression endpoints were eye-level transitions from NPSR to PSR and from baseline PSR to more advanced PSR, staged using fluorescein angiography or ultra-widefield fundus photography.
  • Observed progression rates were 10.7% for baseline NPSR eyes and 17.0% for at-risk baseline PSR eyes, with median follow-up of 7.8 and 11.1 years respectively.
  • Other evaluated covariates—age at diagnosis, sex, genotype, hydroxyurea use, transfusions, chronic red cell exchanges, bone marrow transplantation, and lifetime smoking history—were not associated with progression in the abstract-reported models.
  • Authors’ interpretation supports smoking cessation and closer monitoring/timely intervention among active smokers with PSR, plus longitudinal ophthalmic surveillance, rather than proving that these actions prevent vision loss.
  • Single tertiary referral center may limit generalizability and may overrepresent severe SCR cases.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataIdentify clinical/demographic risk factors associated with SCR progression, highlighting active smoking at PSR diagnosis as a predictor of progression to more advanced PSR.Retrospective cohort; time-to-event analysis with Cox proportional hazards regressionExpand

In plain English

Retrospective time-to-event risk-factor analysis of sickle cell retinopathy (SCR) progression in a single-center Wilmer Eye Institute cohort (317 patients, 620 eyes; patients seen between July 1, 2013 and June 30, 2023) using Cox proportional hazards models. Active smoking at diagnosis of proliferative sickle retinopathy (PSR) was associated with increased hazard of progression to more advanced PSR (HR 2.78, 95% CI 1.50–5.16). Age at diagnosis, sex, genotype, hydroxyurea use, blood transfusions, chronic red cell exchanges, bone marrow transplantation, and lifetime smoking history were not associated with SCR progression in these models.

Key findings

  • Active smoking at PSR diagnosis was associated with increased hazard of progression to more advanced PSR.HR 2.78 (95% CI 1.50–5.16)
  • No association was observed between SCR progression and age at diagnosis, sex, genotype, hydroxyurea use, blood transfusions, chronic red cell exchanges, bone marrow transplantation, or lifetime smoking history in the reported Cox models.
“Cox-proportional hazards models were used to evaluate factors associated with progression.”
2secondary dataEstimate progression rates in sickle cell retinopathy (SCR) over longitudinal follow-up (NPSR→PSR; PSR→more advanced PSR) in a U.S. clinical cohort.Retrospective cohort (secondary data from EMR)Expand

In plain English

Retrospective longitudinal cohort study of sickle cell retinopathy (SCR) patients (317 patients, 620 eyes) at the Wilmer Eye Institute (2013–2023) estimating progression rates from nonproliferative sickle retinopathy (NPSR) to proliferative sickle retinopathy (PSR) and from baseline PSR to more advanced PSR, and evaluating clinical factors associated with progression.

Key findings

  • Progression from baseline nonproliferative sickle retinopathy (NPSR) to proliferative sickle retinopathy (PSR) occurred in 10.7% of eyes.10.7%
  • Progression from baseline PSR to more advanced PSR occurred in 17.0% of at-risk eyes.17.0%
“DESIGN: Retrospective Cohort Study.”
What this piece can’t prove
  • Retrospective cohort design using electronic medical record data (potential for missing or incomplete data and unmeasured confounding).
  • Single tertiary referral center (Wilmer Eye Institute) may limit generalizability.

3 further details could not be confirmed from the summary.

3secondary dataAssess whether qualitative macular OCT findings correlate with peripheral vascular stage and/or predict SCR progression.Retrospective cohort imaging sub-studyExpand

In plain English

In this retrospective cohort, qualitative macular OCT findings were assessed and found not to correlate with baseline peripheral vascular (Goldberg) stage and not to be associated with subsequent sickle cell retinopathy (SCR) progression.

Key findings

  • Qualitative macular OCT findings did not correlate with baseline peripheral vascular stage and were not associated with SCR progression.
“Qualitative assessment of macular optical coherence tomography findings did not correlate with baseline peripheral vascular stage and were not associated with SCR progression.”
What this piece can’t prove
  • Retrospective design (cohort drawn from retrospective electronic medical record review).
  • Qualitative imaging assessment is potentially subjective; without reported methods it is unclear how measurement bias or intergrader variability were addressed.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 37 candidate papers

And 31 more candidates considered.